title: Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial.
abstract: OBJECTIVE
  The hypnotic efficacy of gaboxadol, a selective extrasynaptic GABA A agonist (SEGA), was evaluated in a phase-advance model of transient insomnia.
  
  
  METHODS
  Healthy subjects (18-64 years) completed a randomized, double-blind, parallel group study in which the sleep period was advanced 4h from habitual sleep time. Polysomnographic (PSG) and self-reported sleep measures were used to compare gaboxadol 10mg (N =271) and 15 mg (N =274) versus placebo (N =277).
  
  
  RESULTS
  In the placebo group, the phase-advance procedure disrupted sleep maintenance as measured by PSG wakefulness after sleep onset (WASO) and self-reported WASO (sWASO), and also, to a lesser extent, disrupted sleep onset as measured by PSG latency to persistent sleep (LPS) and self-reported time to sleep onset (sTSO). Both doses of gaboxadol decreased WASO and sWASO versus placebo (p <or= 0.05). Gaboxadol 15 mg also reduced LPS versus placebo (p <or= 0.01) and both doses reduced sTSO versus placebo (p <or= 0.01). PSG and self-reported total sleep time as well as ratings of sleep quality were improved with both gaboxadol doses relative to placebo (all p <or= 0.01 or better). The amount of slow wave sleep (SWS) was greater with both doses of gaboxadol than with placebo (p <or= 0.001). No group differences in the amount of rapid eye movement sleep were found. Most PSG and self-report measures indicated a mild dose response. The percentage of subjects with adverse events was low (<10% in any treatment group) and all were mild or moderate; none were serious and gaboxadol did not impact morning gait or coordination.
  
  
  CONCLUSIONS
  Gaboxadol 10 and 15 mg were efficacious in significantly reducing the sleep maintenance and sleep onset disruption produced by this model of transient insomnia, with effects generally being most pronounced for the 15 mg dose. Gaboxadol also enhanced SWS.
authors.affiliation: St. John's Hospital, St. Louis, MO, USA. jwalsh@stlo.smhs.com
authors.forename: James K
authors.initials: JK
authors.lastname: Walsh
authors.forename: David
authors.initials: D
authors.lastname: Mayleben
authors.forename: Christine
authors.initials: C
authors.lastname: Guico-Pabia
authors.forename: Kristel
authors.initials: K
authors.lastname: Vandormael
authors.forename: Rebecca
authors.initials: R
authors.lastname: Martinez
authors.forename: Steve
authors.initials: S
authors.lastname: Deacon
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D018755:GABA Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017286:Polysomnography / Q000187:drug effects*; D018079:Receptors, GABA / Q000187:drug effects*; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D014851:Wakefulness / Q000187:drug effects
chemical_list: D018755:GABA Agonists; D007555:Isoxazoles; D018079:Receptors, GABA; C015542:gaboxadol